Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) Director Jennifer A. Doudna sold 1,320 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $90.00, for a total transaction of $118,800.00. Following the sale, the director now directly owns 36,011 shares in the company, valued at approximately $3,240,990. This trade represents a 3.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Tempus AI Stock Performance
Shares of TEM opened at $89.44 on Friday. The company’s fifty day moving average is $46.60 and its 200-day moving average is $50.32. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45.
Analysts Set New Price Targets
Several brokerages recently issued reports on TEM. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital dropped their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. TD Cowen restated a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and an average target price of $58.55.
Hedge Funds Weigh In On Tempus AI
Hedge funds have recently bought and sold shares of the business. Kovitz Investment Group Partners LLC acquired a new stake in shares of Tempus AI in the third quarter worth about $1,367,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tempus AI during the 4th quarter valued at about $1,091,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Tempus AI in the 3rd quarter worth approximately $2,726,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Tempus AI during the fourth quarter worth approximately $178,000. 24.22% of the stock is owned by institutional investors and hedge funds.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- How to Invest in the Best Canadian StocksĀ
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- How to Find Undervalued Stocks
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Expert Stock Trading Psychology Tips
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.